Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Sanofi

Market Cap 87B 99.57B 80.48B 75.12B 141B 9,409B 142B 956B 372B 4,626B 374B 366B 16,071B P/E 2026 *
10.8x
P/E 2027 * 10.1x
Enterprise Value 97.47B 112B 90.16B 84.15B 158B 10,541B 159B 1,071B 417B 5,183B 419B 410B 18,005B EV / Sales 2026 *
2.07x
EV / Sales 2027 * 1.87x
Free-Float
89%
Yield 2026 *
5.87%
Yield 2027 * 6.22%
Manager TitleAgeSince
Chief Executive Officer 64 30/04/2026
Director of Finance/CFO 64 31/03/2024
Chief Tech/Sci/R&D Officer 51 10/09/2023
Director TitleAgeSince
Director/Board Member 60 29/04/2019
Director/Board Member 56 27/04/2020
Director/Board Member 64 27/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.88%-.--% - - 99.57B
+0.32%-2.41%+44.49%+140.80% 983B
+1.27%-1.85%+54.41%+39.65% 557B
+6.25%+3.80%+24.13%+67.39% 406B
+1.38%-1.93%+23.33%+16.35% 314B
+1.63%+1.78%+29.75%+18.37% 273B
+1.47%+1.99%+28.40%+34.61% 272B
+2.19%+9.44%-31.93%-43.63% 203B
+2.11%-1.66%+19.14%+50.10% 186B
+0.90%+0.46%+15.09%+59.86% 155B
Average +1.56%-0.92%+22.98%+42.61% 372.26B
Weighted average by Cap. +1.61%-2.22%+31.77%+64.81%

Financials

2026 *2027 *
Net sales 47.07B 53.87B 43.54B 40.64B 76.29B 5,090B 76.84B 517B 201B 2,503B 202B 198B 8,694B 49.98B 57.2B 46.23B 43.15B 81.01B 5,405B 81.6B 549B 214B 2,658B 215B 210B 9,232B
Net income 8.15B 9.32B 7.53B 7.03B 13.2B 881B 13.3B 89.53B 34.84B 433B 35B 34.24B 1,505B 8.95B 10.25B 8.28B 7.73B 14.51B 968B 14.62B 98.43B 38.3B 476B 38.48B 37.64B 1,654B
Net Debt 10.47B 11.98B 9.68B 9.04B 16.96B 1,132B 17.09B 115B 44.76B 557B 44.97B 44B 1,933B 6.3B 7.21B 5.83B 5.44B 10.21B 681B 10.29B 69.26B 26.95B 335B 27.07B 26.49B 1,164B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!